Skip to main contentSkip to navigation
Sirius Investors
Allergy Therapeutics plc

Allergy Therapeutics plc

AGYTF
OTCHealthcare

Allergy Therapeutics plc (AGYTF) Investment Research Dashboard

About Allergy Therapeutics plc (AGYTF) stock analysis

Get live AGYTF stock price $0.15, comprehensive Allergy Therapeutics plc stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time AGYTF stock data and investment insights.

0.15
0.00%Today
Market Cap
756.30M
Volume
7.14K
52W High
0.15
52W Low
0.09

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Allergy Therapeutics plc is a biotechnology firm dedicated to the research, development, and commercialization of innovative treatments for allergic conditions. The company offers a variety of allergen-specific immunotherapies, available as both inje...

Company Information

CEO
Manuel Llobet
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
612

Contact Information

Address
Dominion Way
Country
GB

Investment Analysis & Business Insights

Healthcare
Drug Manufacturers - Specialty & Generic

Investment Highlights

Strong presence in the Healthcare sector with established market position

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Allergy Therapeutics plc shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Allergy Therapeutics plc
  • Investors should consider how Allergy Therapeutics plc fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

756.30M

P/E Ratio (TTM)

-12.23

Beta

0.87

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

78/100 ⭐⭐⭐⭐⭐

Overall
+0.7%
NYSE
+0.6%
NASDAQ
+0.7%
Sector1D1W1MP/EScore
Financial Services+2.2%+3.1%+4.3%19.3
98/100⭐⭐⭐⭐⭐
Healthcare+0.7%+1.3%+1.6%24.1
78/100⭐⭐⭐⭐⭐
Communication Services+1.4%-0.7%+2.9%22.2
74/100⭐⭐⭐⭐⭐
Consumer Defensive-0.2%+1.8%+0.7%29.7
64/100⭐⭐⭐⭐
Basic Materials+0.4%+1.2%-0.2%25.2
61/100⭐⭐⭐⭐
Real Estate-0.5%+0.0%-2.5%29.2
43/100⭐⭐⭐
Energy-2.1%-3.7%-4.1%19.1
39/100⭐⭐
Utilities-1.0%+0.0%-4.4%26.8
37/100⭐⭐
Industrials+0.6%+0.4%-9.9%30.1
23/100
Consumer Cyclical+0.5%-1.5%-5.8%43.0
18/100
Technology+0.6%-1.6%-7.2%40.7
15/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-29.